|
EP0281604B1
(en)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Single polypeptide chain binding molecules
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
|
AU2005250484B2
(en)
|
2004-06-04 |
2011-08-11 |
Genentech, Inc. |
EGFR mutations
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
DE102005028778A1
(de)
|
2005-06-22 |
2006-12-28 |
SUNJÜT Deutschland GmbH |
Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
CN101952312A
(zh)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
|
AU2008343589A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
AU2012256281B2
(en)
*
|
2011-05-16 |
2017-06-15 |
Genzyme Corporation |
Induction of immune tolerance by using methotrexate
|
|
US9574010B2
(en)
|
2011-11-04 |
2017-02-21 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
KR102373193B1
(ko)
|
2012-11-21 |
2022-03-10 |
얀센 바이오테크 인코포레이티드 |
이중특이성 EGFR/c-Met 항체
|
|
EP3929190B1
(en)
|
2014-10-13 |
2024-12-25 |
Yuhan Corporation |
Compounds and compositions for modulating egfr mutant kinase activities
|
|
BR112019010020A2
(pt)
|
2016-11-17 |
2019-08-20 |
Univ Texas |
compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
|
|
MY208668A
(en)
*
|
2019-05-14 |
2025-05-23 |
Janssen Biotech Inc |
Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
|
|
WO2020240434A1
(en)
*
|
2019-05-28 |
2020-12-03 |
Janssen Biotech, Inc. |
Method of providing safe administration of an anti-cd40 antibody
|
|
US20230322933A1
(en)
*
|
2020-06-04 |
2023-10-12 |
Bioinvent International Ab |
Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
|
|
US20230174677A1
(en)
*
|
2021-11-16 |
2023-06-08 |
Janssen Biotech, Inc. |
Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL)
|